Back to results

RecruitingPhase 2Phase 3

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

NCT07284472

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Esperanza Clinical

Murrieta, California, United States

+13 additional locations

Contact

Exciva Clinical Studies

+49 6221-6479990 studies@exciva.com

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2026-02-02
Enrollment: 300 participants
Sponsor: Exciva GmbH
Purpose: treatment

Locations (14)

Esperanza ClinicalMurrieta, California, United States
Josephson Wallack Munshower Neurology PCIndianapolis, Indiana, United States
Precise Research CentersFlowood, Mississippi, United States
Integrative Clinical TrialsBrooklyn, New York, United States
Manhattan Behavioral MedicineNew York, New York, United States
Insight Clinical TrialsIndependence, Ohio, United States
Oregon Health & Science UniversityPortland, Oregon, United States
The Memory ClinicBennington, Vermont, United States
Sunnybrook Health Sciences CentreNorth York, Ontario, Canada
Baycrest Centre for Geriatric CareNorth York, Ontario, Canada
Kawartha CentrePeterborough, Ontario, Canada
Ontario Shores Centre for Mental Health SciencesWhitby, Ontario, Canada
Scottish Brain SciencesEdinburgh, Midlothian, United Kingdom
Scottish Brain SciencesAberdeen, North East Scotland, United Kingdom

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — TrialFind